期刊文献+

嗜麦芽窄食单胞菌体外药物敏感性研究 被引量:7

In vitro susceptibility of Stenotrophomonas maltophilia isolates to antimicrobial agents
下载PDF
导出
摘要 目的比较10种抗菌药物(莫西沙星、加替沙星、左氧氟沙星、环丙沙星、头孢哌酮-舒巴坦、替卡西林一克拉维酸、哌拉西林-三唑巴坦、头孢吡肟、头孢他啶、复方磺胺甲噁唑)对临床分离嗜麦芽窄食单胞菌的体外抗菌活性。方法琼脂稀释法测定10种抗菌药物对来自北京3所医院的200株嗜麦芽窄食单胞菌的MIC值,用WHONET5.3软件进行药敏数据统计分析。结果200株菌对药物的敏感率排序为莫西沙星(84.5%)、加替沙星(79.5%)、左氧氟沙星(76%)、复方磺胺甲嗯唑(72.5%)、头孢哌酮-舒巴坦(41.5%)、替卡西林-克拉维酸(34%)、头孢他啶(23%)、环丙沙星(1 5%)、头孢吡肟(7%)和哌拉西林-三唑巴坦(4.5%)。结论新一代氟喹诺酮类药物如莫西沙星对嗜麦芽窄食单胞菌有较高的体外抗菌活性,是临床治疗嗜麦芽窄食单胞菌感染的较好选择。 Objective To compare the in vitro activity of moxifloxacin with other antimicrobial agents (gatifloxacin, levofloxacin, ciprofloxacin, ceftazidime, cefepime, cefoperazone-sulbactam, piperacillin-tazobactam, ticarcillin-clavulanic acid, trimethoprim-sulfamethoxazole) against the clinical isolates of Stenotrophornonas rnaltophilia. Methods The MICs of ten antimicrobial agents for 200 strains of S. rnaltophilia collected from three hospitals in Beijing were determined by two-fold agar dilution test. The data were analyzed by WHONET 5.3 software. Results The ranking of susceptibility rates from high to low was: moxifloxacin (84.5 % ), gatifloxacin (79.5 % ), levofloxacin (76 % ), trimethoprim-sulfamethoxazole (72.5 %), cefoperazonesulbactam (41.5%), ticarcillin-clavulanic acid (34%), ceftazidime (23%), ciprofloxacin (15%) , cefepime (7%) and piperacillin-tazobactam (4.5 %). New fluoroquinolones, such as moxifloxacin, have high in vitro activity against S. maltophilia. They may be good choice for the treatment of infections caused by S. rnaltophilia.
出处 《中国感染与化疗杂志》 CAS 2006年第5期333-335,共3页 Chinese Journal of Infection and Chemotherapy
关键词 莫西沙星 嗜麦芽窄食单胞菌 Moxifloxacin Stenotrophornonas rnaltophilia
  • 相关文献

参考文献10

  • 1李家泰,李耘,齐慧敏,代表中国细菌耐药监测研究组.2002—2003年中国革兰阴性细菌耐药性监测研究[J].中华检验医学杂志,2005,28(1):19-29. 被引量:296
  • 2National Committee for Clinical Laboratory Standards.Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Sixth Edition; Approved Standard.NCCLS documents M7-A6[S].NCCLS,2003.
  • 3Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement.NCCLS documents M100-S15[S].CLSI/NCCLS,2005.25.
  • 4Denton M,Kerr KG.Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia[J].Clin Microbiol Rev,1998,11:57-80.
  • 5Crispino M,Boccia MC,Bagattini M,et al.Molecular epidemiology of Stenotrophomonas maltophilia in a university hospital[J].J Hosp Infect,2002,52:88-92.
  • 6Tatman-Otkun M,Gurcan S,Ozer B,et al.The antimicrobial susceptibility of Stenotrophomonas maltophilia isolates using three different methods and their genetic relatedness[J].BMC Microbiology,2005,5:24-29.
  • 7Krueger TS,Clark EA,Nix DE.In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations[J].Diagn Microbiol Infect Dis,2001,41:71-78.
  • 8Rolston KV,Kontoyiannis DP,Yadegarynia D,et al.Nonfermentative gram-negative bacilli in cancer patients:increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones[J].Diagn Microbiol Infect Dis,2005,51:215-218.
  • 9Venditti M,Monaco M,Micozzi A,et al.In vitro activity of moxifloxacin against Stenotrophomonas maltophilia blood isolates from patients with hematologic malignancies[J].Clin Microbiol Infect,2001,7:37-39.
  • 10San Gabriel P,Zhou J,Tabibi S,et al.Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis[J].Antimicrob Agents Chemother,2004,48:168-171.

二级参考文献7

  • 1National Committee for Clinical Laboratory Standard, 2002. Performance Standards for Antimicrobial Susceptibility Testing. NCCLS, Wayne, Pa.
  • 2Rhomberg PR, Jones RN , MYSTIC Study Group. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials:report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis, 2003,47:365-372.
  • 3Pfaller MA, Jones RN , MYSTIC Study Group. Antimicrobial susceptibility of inducible Amp C β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Int J Antimicrob Agents, 2002,19:383-388.
  • 4Sader HS, Biedenbach DJ ,Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis, 2003,47:361-364.
  • 5Sader HS, Gales AC, Pfaller MA, et al. Pathogen frequency and resistance patterns in Brazilian hospitals:summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis, 2001,5:200-214.
  • 6李家泰,AllanJ Weinstein,杨敏,中国细菌耐药监测研究组.中国细菌耐药监测研究[J].中华医学杂志,2001,81(1):8-16. 被引量:376
  • 7李家泰,李耘,王进,中国细菌耐药监测研究组.中国医院和社区获得性感染革兰阳性球菌耐药性监测研究[J].中华医学杂志,2003,83(5):365-374. 被引量:198

共引文献295

同被引文献45

引证文献7

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部